KP Tissue Releases Second Quarter 2026 Financial Results
| | | June 30, 2026 | | | December 31, 2025 | |
| | | $ | | | $ | |
| Assets | | | | | | |
| Current assets | | | | | | |
| Cash and cash equivalents | | 165,223 | | | 196,094 | |
| Restricted cash | | 28,434 | | | 46,070 | |
| Trade and other receivables | | 139,144 | | | 143,313 | |
| Receivables from related parties | | 83 | | | 79 | |
| Inventories | | 325,732 | | | 284,183 | |
| Income tax recoverable | | 3,966 | | | 2,963 | |
| Prepaid expenses | | 18,564 | | | 5,381 | |
| | | 681,146 | | | 678,083 | |
| Non-current assets | | | | | ||
| Property, plant and equipment | | 1,425,990 | | | 1,430,206 | |
| Right-of-use assets | | 141,208 | | | 152,243 | |
| Other long-term assets | | 28,596 | | | - | |
| Pensions | | 102,235 | | | 91,118 | |
| Goodwill | | 152,021 | | | 152,021 | |
| Intangible assets | | 37,740 | | | 40,362 | |
| Deferred income tax asset | | 51,593 | | | 64,671 | |
| Total assets | | 2,620,529 | | | 2,608,704 | |
| | | | | | ||
| Liabilities | | | | | ||
| Current liabilities | | | | | ||
| Trade and other payables | | 346,106 | | | 350,831 | |
| Payables to related parties | | 10,891 | | | 13,441 | |
| Dividends payable | | 15,289 | | | 14,853 | |
| Current portion of long-term debt | | 86,832 | | | 98,649 | |
| Current portion of lease liabilities | | 49,126 | | | 43,576 | |
| Current portion of long-term payable to related party | | 5,800 | | | 5,800 | |
| Current portion of provisions | | 5,618 | | | 7,283 | |
| | | 519,662 | | | 534,433 | |
| Non-current liabilities | | | | | ||
| Long-term debt | | 1,076,696 | | | 1,074,148 | |
| Long-term lease liabilities | | 126,335 | | | 139,694 | |
| Long-term payable to related party | | 23,179 | | | 28,064 | |
| Long-term provisions | | 10,873 | | | 12,602 | |
| Pensions | | 17,535 | | | 17,745 | |
| Post-retirement benefits | | 49,342 | | | 48,333 | |
| Deferred income tax liability | | 51,596 | | | 47,140 | |
| Total liabilities | | 1,875,218 | | | 1,902,159 | |
| | | | | | ||
| Equity | | | | | ||
| Share capital | | 342,525 | | | 334,479 | |
| Contributed surplus | | 395,382 | | | 395,382 | |
| Deficit | | (130,415 | ) | | (151,965 | ) |
| Accumulated other comprehensive income | | 95,997 | | | 89,343 | |
| Equity attributable to Kruger Products | | 703,489 | | | 667,239 | |
| Non-controlling interest | | 41,822 | | | 39,306 | |
| Total equity | | 745,311 | | | 706,545 | |
| Total liabilities and equity | | 2,620,529 | | | 2,608,704 | |
Kruger Products Inc.
Unaudited Condensed Consolidated Statements of Income
(thousands of Canadian dollars)
| | ||||||||||||
| | | 3-month | | | 3-month | | | 6-month | | | 6-month | |
| | | period ended | | | period ended | | | period ended | | | period ended | |
| | | June 30, 2026 | | | June 30, 2025 | | | June 30, 2026 | | | June 30, 2025 | |
| | | $ | | | $ | | | $ | | | $ | |
| | | | | | | | | | | | | |
| Revenue | | 550,892 | | | 536,080 | | | 1,095,538 | | | 1,082,190 | |
| Expenses | | | | | | | | | ||||
| Cost of sales | | 440,172 | | | 462,204 | | | 877,045 | | | 913,187 | |
| Selling, general and administrative expenses | | 51,055 | | | 47,157 | | | 102,290 | | | 98,371 | |
| Restructuring costs | | 373 | | | 3,702 | | | 373 | | | 3,702 | |
| Operating income | | 59,292 | | | 23,017 | | | 115,830 | | | 66,930 | |
| Interest expense and other finance costs | | 20,046 | | | 21,306 | | | 39,657 | | | 42,257 | |
| Other expense (income) | | 5,536 | | | (19,941 | ) | | 10,804 | | | (20,284 | ) |
| Income before income taxes | | 33,710 | | | 21,652 | | | 65,369 | | | 44,957 | |
| Current tax expense | | 1,006 | | | 1,078 | | | 1,397 | | | 1,808 | |
| Deferred tax expense (recovery) | | 9,266 | | | (5,612 | ) | | 19,527 | | | 83 | |
| Income tax expense (recovery) | | 10,272 | | | (4,534 | ) | | 20,924 | | | 1,891 | |
| Net income including non-controlling interest | | 23,438 | | | 26,186 | | | 44,445 | | | 43,066 | |
| Net income attributable to non-controlling interest | | 1,281 | | | 4,039 | | | 2,516 | | | 5,524 | |
| Net income attributable to Kruger Products | | 22,157 | | | 22,147 | | | 41,929 | | | 37,542 | |
Kruger Products Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
(thousands of Canadian dollars)
| | | 3-month | | | 3-month | | | 6-month | | | 6-month | |
| | | period ended | | | period ended | | | period ended | | | period ended | |
| | | June 30, 2026 | | | June 30, 2025 | | | June 30, 2026 | | | June 30, 2025 | |
| | | $ | | | $ | | | $ | | | $ | |
| Cash flows from (used in) operating activities | | | | | | | | | | | | |
| Net income including non-controlling interest | | 23,438 | | | 26,186 | | | 44,445 | | | 43,066 | |
| Items not affecting cash | | | | | | | | | ||||
| Depreciation | | 29,399 | | | 43,727 | | | 58,189 | | | 73,616 | |
| Amortization | | 1,532 | | | 2,008 | | | 3,133 | | | 3,980 | |
| Loss (gain) on sale of property, plant and equipment | | (1 | ) | | - | | | - | | | (5 | ) |
| Loss on disposal of leased assets | | (1 | ) | | 23 | | | - | | | 23 | |
| Foreign exchange loss (gain) | | 5,536 | | | (19,941 | ) | | 10,804 | | | (20,284 | ) |
| Interest expense and other finance costs | | 20,046 | | | 21,306 | | | 39,657 | | | 42,257 | |
| Pension and post-retirement benefits | | 2,735 | | | 2,828 | | | 5,400 | | | 5,573 | |
| Provisions | | 1,953 | | | 1,065 | | | 3,186 | | | 3,929 | |
| Income tax expense (recovery) | | 10,272 | | | (4,534 | ) | | 20,924 | | | 1,891 | |
| Total items not affecting cash | | 71,471 | | | 46,482 | | | 141,293 | | | 110,980 | |
| Net change in non-cash working capital | | (42,803 | ) | | (29,513 | ) | | (59,059 | ) | | (54,567 | ) |
| Contributions to pension and post-retirement benefit plans | | (1,049 | ) | | (1,006 | ) | | (2,020 | ) | | (2,015 | ) |
| Provisions paid | | (7,137 | ) | | (4,024 | ) | | (7,137 | ) | | (4,024 | ) |
| Income tax payments, net | | (986 | ) | | (2,465 | ) | | (1,246 | ) | | (1,811 | ) |
| Net cash from operating activities | | 42,934 | | | 35,660 | | | 116,276 | | | 91,629 | |
| | | | | | | | | | ||||
| Cash flows from (used in) investing activities | | | | | | | | | ||||
| Purchases of property, plant and equipment | | (13,588 | ) | | (7,717 | ) | | (28,797 | ) | | (9,862 | ) |
| Purchases of property, plant and equipment related to the Sherbrooke Expansion Project | | (1,036 | ) | | (1,991 | ) | | (1,680 | ) | | (17,377 | ) |
| Government assistance received | | 3,497 | | | - | | | 3,497 | | | 3,150 | |
| Investment in derivative asset | | (27,848 | ) | | - | | | (27,848 | ) | | - | |
| Purchase of software | | (361 | ) | | (1,134 | ) | | (517 | ) | | (1,094 | ) |
| Net cash used in investing activities | | (39,336 | ) | | (10,842 | ) | | (55,345 | ) | | (25,183 | ) |
| | | | | | | | | | ||||
| Cash flows from (used in) financing activities | | | | | | | | | ||||
| Proceeds from long-term debt | | - | | | 9,000 | | | - | | | 31,188 | |
| Repayment of long-term debt | | (17,477 | ) | | (22,507 | ) | | (33,753 | ) | | (32,505 | ) |
| Payment (write-off) of deferred financing fees | | (172 | ) | | 39 | | | (827 | ) | | 7 | |
| Payment of lease liabilities | | (9,139 | ) | | (7,714 | ) | | (19,585 | ) | | (16,737 | ) |
| Change in restricted cash | | 19,752 | | | (25,961 | ) | | 17,636 | | | (27,950 | ) |
| Interest paid on long-term debt | | (20,991 | ) | | (18,995 | ) | | (28,844 | ) | | (31,421 | ) |
| Payment to related party | | (5,800 | ) | | (5,800 | ) | | (5,800 | ) | | (5,800 | ) |
| Dividends paid | | (14,923 | ) | | (28,756 | ) | | (29,776 | ) | | (28,756 | ) |
| Proceeds from issuing partnership units | | 3,995 | | | 12,686 | | | 7,981 | | | 12,686 | |
| Net cash used in financing activities | | (44,755 | ) | | (100,834 | ) | | (92,968 | ) | | (99,288 | ) |
| Effect of exchange rate changes on cash and cash equivalents held in foreign currency | | 467 | | | (1,284 | ) | | 1,166 | | | (1,311 | ) |
| Decrease in cash and cash equivalents during the period | | (40,690 | ) | | (77,300 | ) | | (30,871 | ) | | (34,153 | ) |
| Cash and cash equivalents - Beginning of period | | 205,913 | | | 141,778 | | | 196,094 | | | 119,460 | |
| Cash and cash equivalents - End of period | | 165,223 | | | 64,478 | | | 165,223 | | | 85,307 | |
Kruger Products Inc.
Unaudited Segment and Geographic Results
(thousands of Canadian dollars)
| | | 3-month | | | 3-month | | | 6-month | | | 6-month | |
| | | period ended | | | period ended | | | period ended | | | period ended | |
| | | June 30, 2026 | | | June 30, 2025 | | | June 30, 2026 | | | June 30, 2025 | |
| | | $ | | | $ | | | $ | | | $ | |
| Segment Information | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Segment Revenue | | | | | | | | | | | | |
| Consumer | | 457,561 | | | 449,222 | | | 919,289 | | | 914,412 | |
| AFH | | 93,331 | | | 86,858 | | | 176,249 | | | 167,778 | |
| Revenue from external customers | | 550,892 | | | 536,080 | | | 1,095,538 | | | 1,082,190 | |
| | | | | | | | | | ||||
| Other segment items | | | | | | | | | ||||
| Consumer | | 372,252 | | | 380,038 | | | 750,046 | | | 769,176 | |
| AFH | | 84,836 | | | 77,895 | | | 161,438 | | | 156,026 | |
| Corporate and other costs | | 3,207 | | | 5,669 | | | 6,527 | | | 8,743 | |
| Total other segment items | | 460,295 | | | 463,602 | | | 918,011 | | | 933,945 | |
| | | | | | | | | | ||||
| Adjusted EBITDA | | | | | | | | | ||||
| Consumer | | 85,309 | | | 69,184 | | | 169,243 | | | 145,236 | |
| AFH | | 8,495 | | | 8,963 | | | 14,811 | | | 11,752 | |
| Corporate and other costs | | (3,207 | ) | | (5,669 | ) | | (6,527 | ) | | (8,743 | ) |
| Total Adjusted EBITDA | | 90,597 | | | 72,478 | | | 177,527 | | | 148,245 | |
| | | | | | | | | | ||||
| Reconciliation to net income (loss) | | | | | | | | | ||||
| Depreciation and amortization | | 30,933 | | | 45,736 | | | 61,324 | | | 77,596 | |
| Interest expense and other finance costs | | 20,046 | | | 21,306 | | | 39,657 | | | 42,257 | |
| Loss on disposal of property, plant and equipment | | (1 | ) | | 23 | | | - | | | 18 | |
| Restructuring costs, net | 373 | 3,702 | 373 | 3,702 | ||||||||
| Foreign exchange loss (gain) | | 5,536 | | | (19,941 | ) | | 10,804 | | | (20,284 | ) |
| Income before income taxes | | 33,710 | | | 21,652 | | | 65,369 | | | 44,956 | |
| Income tax expense (recovery) | | 10,272 | | | (4,534 | ) | | 20,924 | | | 1,891 | |
| Net income including non-controlling interest | | 23,438 | | | 26,186 | | | 44,445 | | | 43,065 | |
| | | | | | | | | | ||||
| Geographic Revenue | | | | | | | | | ||||
| | | | | | | | | | ||||
| Canada | | 291,910 | | | 299,654 | | | 580,864 | | | 586,177 | |
| US | | 258,982 | | | 236,426 | | | 514,674 | | | 496,013 | |
| Total revenue | | 550,892 | | | 536,080 | | | 1,095,538 | | | 1,082,190 | |
KP Tissue Inc.
Unaudited Condensed Statements of Financial Position
(thousands of Canadian dollars)
| | | June 30, 2026 | | | December 31, 2025 | |
| | | $ | | | $ | |
| Assets | | | | | | |
| Current assets | | | | | | |
| Dividends receivable | | 2,106 | | | 1,803 | |
| | | 2,106 | | | 1,803 | |
| Non-current assets | | | | | ||
| Investment in associate | | 72,717 | | | 69,799 | |
| Total assets | | 74,823 | | | 71,602 | |
| | | | | | ||
| Liabilities | | | | | ||
| Current liabilities | | | | | ||
| Dividends payable | | 2,106 | | | 1,803 | |
| Total liabilities | | 2,106 | | | 1,803 | |
| | | | | | ||
| Equity | | | | | ||
| Common shares | | 23,133 | | | 23,001 | |
| Contributed surplus | | 144,819 | | | 144,819 | |
| Deficit | | (113,082 | ) | | (114,985 | ) |
| Accumulated other comprehensive income | | 17,847 | | | 16,964 | |
| Total equity | | 72,717 | | | 69,799 | |
| Total liabilities and equity | | 74,823 | | | 71,602 | |
KP Tissue Inc.
Unaudited Condensed Statements of Income
(thousands of Canadian dollars, except share and per share amounts)
| | | 3-month | | | 3-month | | | 6-month | | | 6-month | |
| | | period ended | | | period ended | | | period ended | | | period ended | |
| | | June 30, 2026 | | | June 30, 2025 | | | June 30, 2026 | | | June 30, 2025 | |
| | | $ | | | $ | | | $ | | | $ | |
| Share of income | | 2,659 | | | 2,755 | | | 5,049 | | | 4,672 | |
| Depreciation of fair value increments | | (269 | ) | | (279 | ) | | (539 | ) | | (563 | ) |
| Equity income | | 2,390 | | | 2,476 | | | 4,510 | | | 4,109 | |
| Dilution gain | | 53 | | | 95 | | | 112 | | | 209 | |
| Net income | | 2,443 | | | 2,571 | | | 4,622 | | | 4,318 | |
| | | | | | | | | | ||||
| Basic and diluted earning per share | | 0.24 | | | 0.26 | | | 0.46 | | | 0.43 | |
| | | | | | | | | | ||||
| Weighted average number of shares outstanding | | 10,026,884 | | | 9,999,883 | | | 10,024,084 | | | 9,996,544 | |
KP Tissue Inc.
Unaudited Statements of Cash Flows
(thousands of Canadian dollars)
| | | 3-month | | | 3-month | | | 6-month | | | 6-month | |
| | | period ended | | | period ended | | | period ended | | | period ended | |
| | | June 30, 2026 | | | June 30, 2025 | | | June 30, 2026 | | | June 30, 2025 | |
| | | $ | | | $ | | | $ | | | $ | |
| Cash flows from (used in) operating activities | | | | | | | | | | | | |
| Net income | | 2,443 | | | 2,571 | | | 4,622 | | | 4,318 | |
| Items not affecting cash | | | | | | | | | ||||
| Equity income | | (2,390 | ) | | (2,476 | ) | | (4,510 | ) | | (4,109 | ) |
| Dilution gain | | (53 | ) | | (95 | ) | | (112 | ) | | (209 | ) |
| Total items not affecting cash | | (2,443 | ) | | (2,571 | ) | | (4,622 | ) | | (4,318 | ) |
| Net cash from operating activities | | - | | | - | | | - | | | - | |
| | | | | | | | | | ||||
| Cash flows from (used in) investing activities | | | | | | | | | ||||
| Dividends received, net | | 1,744 | | | 1,746 | | | 3,476 | | | 3,490 | |
| Net cash from investing activities | | 1,744 | | | 1,746 | | | 3,476 | | | 3,490 | |
| | | | | | | | | | ||||
| Cash flows from (used in) financing activities | | | | | | | | | ||||
| Dividends paid, net | | (1,744 | ) | | (1,746 | ) | | (3,476 | ) | | (3,490 | ) |
| Net cash used in financing activities | | (1,744 | ) | | (1,746 | ) | | (3,476 | ) | | (3,490 | ) |
| Increase in cash and cash equivalents during the period | | - | | | - | | | - | | | - | |
| Cash and cash equivalents - Beginning of period | | - | | | - | | | - | | | - | |
| Cash and cash equivalents - End of period | | - | | | - | | | - | | | - | |
To view the source version of this press release, please visit
Source: KP Tissue Inc.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.


Comments
No comment